As of June 30, 2026, Concord Medical Co Ltd carries a market capitalization of 1.05B, placing it among publicly traded companies globally. Its enterprise value stands at 1.04B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.05B |
| Enterprise Value | 1.04B |
As of June 30, 2026, Concord Medical Co Ltd has 33.33M shares outstanding.
| Shares Outstanding | 33.33M |
These figures are as of June 30, 2026.
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.49 |
As of June 30, 2026, Concord Medical Co Ltd maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.66 |
| Quick Ratio | 0.67 |
| Debt / Equity | 25.18 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 50.00 |
As of the close on November 17, 2026, Concord Medical Co Ltd's stock has gained approximately 14.04% over the past 52 weeks. The 50-day moving average sits at 31.22, while the 200-day moving average is 29.84.
| 52-Week Price Change | 14.04% |
| 50-Day Moving Average | 31.22 |
| 200-Day Moving Average | 29.84 |
As of June 30, 2026, Concord Medical Co Ltd holds 225.93M in cash and equivalents against 189.28M in total debt, resulting in a net debt position of -92.99M. Total book value stands at 725.33M, with working capital of 222.52M providing operational flexibility.
| Cash & Cash Equivalents | 225.93M |
| Total Debt | 189.28M |
| Net Debt | -92.99M |
| Equity (Book Value) | 725.33M |
| Book Value Per Share | 21.76 |
| Working Capital | 222.52M |
Already premium?